AGP Executive Report
Last update: 7 hours agoPharma & Medtech Compliance: Ivoclar is rolling out a verification program and a list of authorized distributors to help dental clinics avoid risks from counterfeit and gray-market products. EU Health Industry: Pfizer and BioNTech secured European Commission marketing authorization for their XFG-adapted COVID-19 vaccine (valid across EU plus Iceland, Liechtenstein and Norway), with manufacturing already underway for the respiratory season. Specialty Oncology Deal: IMPACT Therapeutics licensed senaparib to Pharmanovia for exclusive manufacturing, development and commercialization across Europe, UK, EEA states including Liechtenstein, Switzerland, and broader regions; total deal value up to €423.5M plus royalties. Energy & Logistics Shock: A Europe-wide heatwave and drought are pushing the Rhine and Danube to record lows, forcing nuclear output cuts in Hungary and threatening industrial throughput and shipping capacity. Industrial Coatings for Composites: Oerlikon Balzers promoted its Baldia CVD diamond coatings aimed at reducing abrasive wear and improving tool life for composite machining. Crypto Regulation Watch (Liechtenstein angle): ESMA added 15 crypto-asset service providers to the MiCA register (now 309), while separate reporting flagged Binance app availability issues in some EU markets and noted Liechtenstein-linked crypto activity tied to sanctioned stablecoin marketing.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.